Hopital Des Enfants
- Address
- lock Available on a paid plan
Hopital Des Enfants - Pediatric Research Center
Hopital Des Enfants is a leading pediatric clinical research institution specializing in comprehensive care and innovative treatment trials for children and adolescents across diverse medical conditions. The center demonstrates exceptional expertise in rare genetic disorders, pediatric oncology, and complex childhood diseases requiring specialized therapeutic approaches.
- Pediatric oncology including neuroblastoma, osteosarcoma, Ewing sarcoma, acute lymphoblastic leukemia, and diffuse midline gliomas with advanced targeted therapies and immunotherapy protocols
- Rare genetic conditions such as achondroplasia, spinal muscular atrophy, Duchenne muscular dystrophy, Prader-Willi syndrome, and familial hypercholesterolemia
- Pediatric inflammatory and autoimmune diseases including Crohn's disease, ulcerative colitis, juvenile psoriatic arthritis, systemic lupus erythematosus, and childhood nephrotic syndrome
- Growth disorders, metabolic conditions, neurological disorders including childhood epilepsy and Dravet syndrome, and complex pediatric obesity management
The center maintains active participation in international collaborative networks and multi-center platform trials, investigating novel biologics, gene therapies, and precision medicine approaches. Research programs encompass early-phase safety studies through advanced efficacy trials, with particular emphasis on pharmacokinetic optimization for pediatric populations and long-term safety monitoring. The institution's commitment extends to optimizing antimicrobial stewardship in community-acquired pneumonia and advancing treatment paradigms for both common and ultra-rare childhood conditions affecting growth, development, and quality of life.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 15 therapeutic areas and 15 of 72 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 65 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 18 by active trials.
- 1Biomarin Pharmaceutical Inc.3active
lock +17 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Biomarin Pharmaceutical Inc.3trials
lock +10 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Hopital Des Enfants
lock Showing 1 of 45 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Comparative Study of Somapacitan and Somatropin in Pediatric Patients with Short Stature Due to SGA, Turner Syndrome, Noonan Syndrome, or Idiopathic Short Stature | Novo Nordisk A/S | Phase III | Not Recruiting | Aug 2022 | — |
IMP list
lock Showing 1 of 72 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Temozolomide | 3 | Unknown | 2015-05-05 | 2026-07-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.